Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
First-line Avelumab Maintenance Under Real-world Evaluation in Metastatic Urothelial Carcinoma
The baseline characteristics, treatment patterns, and responses to first-line platinum-based chemotherapy for patients with locally advanced or metastatic urothelial carcinoma receiving avelumab maintenance therapy were consistent with responses to usual therapy paradigms in the first-line induction setting.
Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
February 20th 2023Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.
Vedolizumab Plus Standard Prophylaxis Reduces Rate of Lower GI aGVHD
The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.
Tisa-cel Reinfusion Shows Potential as HSCT Bridging Therapy in Pediatric B-ALL
February 19th 2023Second infusion with tisagenlecleucel after prior tisagenlecleucel infusion produced short durations of minimal residual disease-negative responses in children and young adults with B-cell acute lymphoblastic leukemia.
Nivolumab Plus Cabozantinib Shows Sustained Survival Advantage in Advanced RCC
The combination of nivolumab and cabozantinib produced prolonged progression-free survival and higher response rates compared with sunitinib alone as frontline therapy in patients with advanced renal cell carcinoma, regardless of International Metastatic RCC Database Consortium risk status.
Ide-Cel Improves PFS and ORR in Triple-Class Exposed, Early R/R Multiple Myeloma
February 19th 2023Idecabtagene vicleucel demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and objective response compared with standard of care approaches in patients with triple-class-exposed relapsed/refractory multiple myeloma.
Chronic Opioid Use Following ASCT Linked With Poor Survival Outcomes in Multiple Myeloma
February 18th 2023Patients with multiple myeloma who were treated with autologous stem cell transplantation were found to be utilizing chronic opioids at high rates, in turn leading to worse overall survival outcomes at 6 months of follow-up.
Cabozantinib After CPI-Based Combination Therapy Showcases Early Efficacy in Advanced RCC
Treatment with cabozantinib elicited responses in patients with locally advanced or metastatic renal cell carcinoma with a clear-cell component who had progressed after first-line treatment with checkpoint inhibitor–based combination therapy.
Atezolizumab/Chemotherapy Trends Toward Improved OS in Urothelial Carcinoma
February 18th 2023First-line atezolizumab plus platinum-based chemotherapy and gemcitabine trended toward improved overall survival compared with placebo plus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.
Nivolumab Displays Sustained Survival Benefits in Urothelial Carcinoma
February 18th 2023At extended follow-up, nivolumab monotherapy showed improved disease-free survival, non-urothelial tract recurrence-free survival, and disease-specific survival vs placebo in patients with resected, high-risk muscle-invasive urothelial carcinoma.
Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple Myeloma
February 18th 2023Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.
Dr. Srour on Orca-Q Transplantation in Hematologic Malignancies
February 18th 2023Samer A. Srour, MB ChB, MS, discusses findings with Orca-Q, an investigational therapy consisting of enriched CD34+ stem cells plus T-cell subsets, in patients with high-risk hematologic malignancies eligible for myeloablative conditioning and allogeneic stem cell transplant.
Niraparib Plus Abiraterone/Prednisone Maintains rPFS Benefit in HRR Gene–Altered mCRPC
February 17th 2023The combination of niraparib, abiraterone acetate, and prednisone produced prolonged survival and delayed progression rates in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
Dr. Aggarwal on Characteristics Associated With PSA PFS from the PRESTO Trial in Prostate Cancer
February 17th 2023Rahul Aggarwal, MD, discusses the association between baseline characteristics and prostate-specific antigen progression-free survival in patients with high-risk biochemically relapsed prostate cancer from the phase 3 PRESTO trial.
Sacituzumab Govitecan Benefit Is Consistent Following CPI in Platinum-Ineligible mUC
Treatment with the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan elicited an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer following progression on an immune checkpoint inhibitor, according to the primary analysis of TROPHY-U-01 cohort 2.
Potential Biomarkers of Response Identified for Enfortumab Vedotin in Advanced Urothelial Cancer
February 17th 2023Tumor mutational burden and alterations in CDKN2A, CDKN2B, and MTAP were among several biomarkers that were predictive of response to enfortumab vedotin in patients with advanced urothelial carcinoma, according to findings from a retrospective analysis.
Novel Therapies Are Needed to Reduce Cost Burden With AlloHCT, GVHD
Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
